A patient with poorly controlled diabetes presents with early signs of nephropathy, dyslipidemia, retinopathy, and peripheral neuropathy. Which nursing intervention should be prioritized to address the immediate risk of further complications?

C) Collaborate with the healthcare provider to adjust the patient's diabetes medication regimen.

A) Educate the patient on the importance of a low sodium diet to manage blood pressure.

B) Arrange for an immediate referral to an ophthalmologist for further retinal evaluation.

C) Collaborate with the healthcare provider to adjust the patient's diabetes medication regimen.

D) Schedule regular foot care appointments to prevent diabetic foot ulcers.

A 55-year-old patient with type 2 diabetes presents with a hemoglobin A1c of 9.2%, serum creatinine of 1.4 mg/dL, and an eGFR of 58 mL/min/1.73 m². The patient also exhibits signs of diabetic retinopathy and peripheral neuropathy. Which of the following nursing interventions should be prioritized to address the patient's condition comprehensively?

D) Collaborate with the healthcare team to adjust the patient's diabetes medication regimen.

A) Educate the patient on dietary changes to manage dyslipidemia effectively.

B) Refer the patient to a nephrologist for evaluation of renal function.

C) Initiate an exercise program to improve peripheral circulation and reduce neuropathy symptoms.

D) Collaborate with the healthcare team to adjust the patient's diabetes medication regimen.

A patient with type 2 diabetes has been started on a sodium-glucose co-transporter-2 (SGLT2) inhibitor and reports increased urination and occasional dizziness. Considering the medication's mechanism of action, what is the most appropriate nursing intervention to address these symptoms?

C) Instruct the patient to monitor blood pressure regularly and report hypotensive episodes.

A) Encourage the patient to increase fluid intake to prevent dehydration.

B) Advise the patient to decrease sodium intake to control blood pressure.

C) Instruct the patient to monitor blood pressure regularly and report hypotensive episodes.

D) Suggest the patient consume more carbohydrates to prevent hypoglycemia.

A patient on a sodium-glucose co-transporter-2 (SGLT2) inhibitor reports increased urination and occasional dizziness. Which nursing intervention is most appropriate to address the patient's current symptoms and ensure safety?

C) Recommend monitoring blood pressure at home and report any significant changes.

A) Encourage the patient to increase fluid intake to offset dehydration.

B) Advise the patient to limit physical activity to prevent dizziness.

C) Recommend monitoring blood pressure at home and report any significant changes.

D) Suggest taking the medication with meals to reduce side effects.

A patient on an angiotensin receptor blocker (ARB) and SGLT2 inhibitor presents with new-onset bilateral pitting edema and a slight increase in serum potassium. What is the most appropriate nursing intervention to address the patient's current symptoms while monitoring potential complications?

B) Educate the patient on reducing dietary potassium intake.

A) Encourage increased fluid intake to help reduce edema.

B) Educate the patient on reducing dietary potassium intake.

C) Promote regular daily exercise to improve circulation.

D) Increase the dose of ARB to enhance blood pressure control.

A patient on angiotensin receptor blocker (ARB) therapy presents with bilateral pitting edema and mild hyperkalemia. Which nursing intervention is most appropriate to address these findings while maintaining effective blood pressure control?

B) Educate the patient on the importance of a low-potassium diet

A) Encourage increased fluid intake to promote kidney function

B) Educate the patient on the importance of a low-potassium diet

C) Advise the patient to avoid all physical activity to reduce edema

D) Recommend the patient stop taking the ARB immediately

A patient with a history of heart failure and diabetic nephropathy is experiencing persistent ankle swelling, increased thirst, and fatigue after starting a low-dose diuretic. Lab results show mild hyponatremia and an elevated BNP level. What is the most appropriate nursing intervention to address the patient's condition while awaiting the cardiology referral?

C) Monitor the patient’s daily weight and report significant changes to the healthcare provider.

A) Increase the dosage of the diuretic to enhance fluid removal.

B) Educate the patient on reducing fluid intake to prevent further hyponatremia.

C) Monitor the patient’s daily weight and report significant changes to the healthcare provider.

D) Advise the patient to increase dietary sodium intake to correct hyponatremia.

A patient on low-dose diuretic therapy presents with increased thirst, fatigue, and mild hyponatremia. The serum potassium is 4.8 mEq/L, and the BNP is elevated at 150 pg/mL. What is the most appropriate nursing intervention to address the patient's current symptoms and lab findings?

C) Advise the patient to report any sudden weight gain, worsening edema, or shortness of breath promptly.

A) Instruct the patient to increase their fluid intake to counteract the diuretic's effects.

B) Educate the patient on reducing dietary sodium to help manage the edema.

C) Advise the patient to report any sudden weight gain, worsening edema, or shortness of breath promptly.

D) Recommend the patient discontinue the diuretic until the cardiology evaluation is completed.

A patient with type 2 diabetes and heart failure is experiencing increased thirst and frequent urination. Recent labs show elevated HbA1c and creatinine. The healthcare team has added an SGLT2 inhibitor to the patient's regimen. Which nursing action is the priority to address potential complications from the new medication?

B) Assess for signs of fluid volume depletion such as dizziness and hypotension

A) Monitor blood glucose levels regularly for hypoglycemia

B) Assess for signs of fluid volume depletion such as dizziness and hypotension

C) Educate the patient on recognizing signs of urinary tract infections

D) Review the patient's dietary intake to ensure adequate carbohydrate consumption

A 62-year-old patient with a history of type 2 diabetes and heart failure has been started on an SGLT2 inhibitor to improve glycemic control and provide renal protection. Which of the following nursing interventions should be prioritized to monitor for potential complications associated with the new medication?

B) Assess for symptoms of urinary tract infections, like dysuria and frequency.

A) Monitor for signs of hypoglycemia, such as confusion and tremors.

B) Assess for symptoms of urinary tract infections, like dysuria and frequency.

C) Obtain daily weights and check for signs of fluid retention.

D) Monitor liver function tests for elevations in ALT and AST levels.

Diabetes - Nursing Case Study

Pathophysiology

• Primary mechanism: Insulin resistance - In type 2 diabetes, body cells become less responsive to insulin, a hormone necessary for glucose uptake, leading to elevated blood sugar levels. The pancreas compensates by producing more insulin, but over time, this compensatory mechanism fails.

• Secondary mechanism: Impaired insulin secretion - As the disease progresses, the pancreatic beta cells responsible for insulin production become dysfunctional or die. This further exacerbates hyperglycemia as insulin availability decreases.

• Key complication: Chronic hyperglycemia - Persistent high blood sugar can result in damage to blood vessels and nerves, leading to complications such as cardiovascular disease, neuropathy, retinopathy, and nephropathy, affecting multiple organ systems and increasing morbidity.

Patient Profile

Demographics:

52-year-old male, construction worker

History:

• Type 2 Diabetes diagnosed 8 years ago, hypertension, hyperlipidemia

• Metformin 1000 mg twice daily, Lisinopril 20 mg daily, Atorvastatin 40 mg daily

• No known drug allergies

Current Presentation:

• Chief complaint: Increased fatigue and blurry vision

• Key symptoms: Numbness in feet, frequent urination, and increased thirst

• Vital signs: Blood pressure 145/90 mmHg, heart rate 88 bpm, respiratory rate 18 breaths per minute, temperature 98.6°F, blood glucose 210 mg/dL

Section 1

New Diagnostic Results:

Following the initial assessment, the healthcare team proceeded with a series of diagnostic tests to gain further insight into the patient's condition. A comprehensive metabolic panel revealed a slight elevation in serum creatinine at 1.4 mg/dL, indicating potential early kidney involvement, which is consistent with diabetic nephropathy. The estimated glomerular filtration rate (eGFR) was 58 mL/min/1.73 m², suggesting a moderate decrease in renal function. Additionally, a lipid panel showed total cholesterol at 230 mg/dL, LDL cholesterol at 150 mg/dL, and HDL cholesterol at 38 mg/dL, underscoring persistent dyslipidemia despite current statin therapy.

The patient's hemoglobin A1c was measured at 9.2%, indicating suboptimal glycemic control over the past three months. A fundoscopy was performed due to the complaint of blurry vision, revealing the presence of microaneurysms and cotton wool spots, suggestive of non-proliferative diabetic retinopathy. The numbness in the feet prompted a monofilament test, which showed decreased sensation, confirming peripheral neuropathy.

These diagnostic results underscore the importance of intensifying diabetes management to prevent further complications. The healthcare team must consider adjusting the patient's current therapeutic regimen to achieve better glycemic, lipid, and blood pressure control. This may involve introducing additional oral hypoglycemic agents or insulin therapy, along with reinforcing lifestyle modifications. Early nephrology referral and ophthalmology follow-up are also warranted to address the renal and retinal findings, respectively. These steps are crucial to altering the patient's disease trajectory and minimizing the risk of progression to more severe complications.

Section 2

Change in Patient Status:

Two weeks following the adjustment in the patient's therapeutic regimen, including the introduction of a sodium-glucose co-transporter-2 (SGLT2) inhibitor and an increase in the dosage of the statin, the patient returned for a follow-up visit. Clinically, the patient reported a slight improvement in blood sugar monitoring at home, with fasting glucose levels now averaging around 150 mg/dL. However, the patient mentioned experiencing increased frequency of urination and occasional episodes of dizziness, raising concerns about possible side effects from the new medication and the need for further evaluation.

Upon examination, vital signs revealed a blood pressure of 138/86 mmHg and a heart rate of 92 beats per minute. While the blood pressure remained above target, it was an improvement from previous readings. The patient's weight had decreased by 3 pounds, potentially indicating a positive response to lifestyle modifications and the new medication. A repeat comprehensive metabolic panel demonstrated stable kidney function, with serum creatinine holding at 1.3 mg/dL and an eGFR of 60 mL/min/1.73 m², suggesting that renal function had not further deteriorated.

Despite these improvements, the patient's lipid profile showed minimal change, with LDL cholesterol only slightly reduced to 145 mg/dL. The ongoing dyslipidemia, alongside the persistent mild hypertension, necessitated a re-evaluation of the patient's cardiovascular risk management. The healthcare team decided to introduce an angiotensin receptor blocker (ARB) to better address both blood pressure and renal protection. Additionally, periodic monitoring of renal function and electrolyte levels was advised to detect any adverse effects early. These efforts aimed to refine and optimize the patient's management plan, ultimately mitigating the risk of further complications and promoting long-term health stability.

Section 3

Two weeks after the introduction of the angiotensin receptor blocker (ARB), the patient returned for another follow-up visit. Initially, the patient reported feeling more energetic and experiencing fewer episodes of dizziness, suggesting some improvement in overall well-being. However, the frequency of urination persisted, and the patient now described a new onset of mild swelling in the ankles, particularly noticeable by the end of the day. This raised concerns about fluid retention potentially associated with the new ARB therapy.

During the examination, vital signs revealed a blood pressure of 130/82 mmHg and a heart rate of 88 beats per minute, indicating a modest improvement in hypertension control. However, physical examination confirmed bilateral pitting edema in the lower extremities. The patient's weight had increased by 2 pounds since the last visit, likely reflective of fluid retention. A repeat comprehensive metabolic panel showed stable kidney function, with serum creatinine at 1.3 mg/dL and an eGFR of 58 mL/min/1.73 m², but there was a slight increase in serum potassium levels to 5.2 mEq/L, which warranted close monitoring.

The clinical team reviewed these findings and considered potential adjustments to the therapeutic regimen. The persistence of increased urination and the development of edema suggested the need for a thorough evaluation of the existing medication's side effects, particularly focusing on the balance between the SGLT2 inhibitor and the ARB. The team decided to initiate a low-dose diuretic to manage fluid retention while closely monitoring electrolyte levels, especially potassium, to prevent hyperkalemia. This approach aimed to optimize blood pressure control, reduce edema, and manage cardiovascular risks without compromising renal function or causing additional adverse effects. The patient was scheduled for a follow-up visit in two weeks, with instructions to report any significant changes in symptoms or weight gain immediately.

Section 4

Two weeks later, the patient returned for another follow-up visit, reporting some improvement in the ankle swelling since starting the low-dose diuretic. However, they now experienced increased thirst and fatigue, raising concerns about the potential impact on their hydration status and electrolyte balance. Upon examination, the patient's blood pressure was recorded at 128/80 mmHg, and the heart rate was 86 beats per minute, indicating stable cardiovascular parameters. Despite these stable vital signs, a repeat physical examination revealed persistent, though slightly reduced, bilateral pitting edema in the lower extremities.

The clinical team ordered a comprehensive metabolic panel and noted several new diagnostic results. The serum potassium level had normalized to 4.8 mEq/L, suggesting effective management of hyperkalemia. However, the serum sodium level had decreased to 134 mEq/L, indicating mild hyponatremia, possibly due to the diuretic therapy. Additionally, the B-type natriuretic peptide (BNP) level was elevated at 150 pg/mL, hinting at potential early-stage heart failure that could be contributing to the edema and fatigue.

In light of these findings, the clinical team engaged in a detailed discussion about the patient's current status and the potential need for further adjustments to their treatment plan. They considered whether to continue the diuretic at the current dose or to investigate other underlying causes of the patient's symptoms, such as possible heart failure or worsening diabetic nephropathy. The team decided to schedule a cardiology referral for further evaluation of the elevated BNP levels and potential heart failure, while maintaining a cautious approach to medication management to avoid exacerbating the patient's electrolyte imbalances or renal function. The patient was advised to monitor their symptoms closely and to report any worsening of edema, fatigue, or changes in urination promptly.

Section 5

Over the following week, the patient began to experience additional symptoms, including a persistent dry mouth and increased frequency of urination, which raised concerns about worsening glycemic control. Recognizing the potential for evolving complications, the clinical team prioritized a thorough review of the patient's diabetic status. A follow-up HbA1c test was ordered, revealing an elevated level of 8.2%, up from a previous reading of 7.5% three months ago. This indicated a deterioration in blood glucose management, likely contributing to the patient's increased thirst and fatigue.

The clinical team also noted a slight increase in the patient's creatinine level to 1.5 mg/dL, suggesting a potential decline in renal function, possibly exacerbated by the ongoing diuretic therapy. This prompted a re-evaluation of the current medication regimen, considering the dual challenges of managing both diabetes and potential heart failure. To address these issues, the team decided to introduce an SGLT2 inhibitor, aiming to improve glycemic control while providing renal protection and beneficial cardiovascular effects.

A follow-up plan was devised, with the patient scheduled for a closer monitoring of renal function and electrolyte levels, particularly focusing on sodium and potassium, given the recent hyponatremia. The clinical team also emphasized the importance of lifestyle modifications, including dietary adjustments and weight management, to support overall treatment goals. The patient was instructed to maintain an open line of communication with the healthcare team, promptly reporting any new or worsening symptoms, such as significant changes in urination or sudden onset of shortness of breath, to proactively address potential complications and optimize outcomes.